Exhibit B

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK

ROBERT CORWIN, Individually, and On

Behalf of All Others Similarly Situated,

Electronically Filed

Plaintiff,

V.

Civil Action No.: 1:07-cv-06728-DC (ECF Case)

BERND R. SEIZINGER, MARTINE GEORGE, MARCEL ROSENCZWEIG, and

GPC BIOTECH AG,

Hon. Denny Chin

Defendants.

(Additional captions on the following pages)

DECLARATION OF AXXION S.A. LUXEMBURG, ON BEHALF OF ITS AKROBAT FUND-VALUE, IN SUPPORT OF ITS MOTION FOR CONSOLIDATION, APPOINTMENT AS LEAD PLAINTIFF AND APPROVAL OF SELECTION OF LEAD COUNSEL ISTVAN TEMESFOI, Individually, and On Behalf of All Others Similarly Situated,

٧.

Electronically Filed

Plaintiff,

Civil Action No.: 1:07-cv-07016-DC

(ECF Case)

GPC BIOTECH AG, BERND R. SEIZINGER, : MARTINE GEORGE and, MARCEL ROSENCZWEIG,

Hon. Denny Chin

Defendants.

AUDREY DANG, Individually, and On Behalf: of All Others Similarly Situated,

Electronically Filed

Plaintiff,

Civil Action No.: 1:07-cv-07476-DC

(ECF Case)

GPC BIOTECH AG, BERND R. SEIZINGER, : MARTINE GEORGE and, MARCEL ROSENCZWEIG,

Hon. Denny Chin

Defendants.

v.

I, Roman Mertes, declare as follows:

- 1. I respectfully submit this Declaration in support of the motion of Axxion S.A. Luxemburg, on behalf of its Akrobat Fund-Value ("Axxion"), for consolidation, appointment as lead plaintiff in the securities action against GPC Biotech AG ("GPC"), and approval of its selection of Labaton Sucharow LLP as lead counsel.
- I am the Managing Director of Axxion and an authorized signatory for Axxion.
 Axxion is an investment firm established pursuant to Luxemburgian law. Axxion manages assets totaling approximately €1.7 billion.
- 3. Axxion is fully authorized under Luxemburgian law to establish and manage investment funds. The Axxion family of funds includes the Akrobat Fund. The Akrobat Fund is a distinct legal entity, separate from Axxion and the other funds managed by Axxion.
- 4. The Akrobat Fund-Value ("Value") and the Akrobat Fund-Europa ("Europa") are special assets/partial funds in the umbrella Akrobat Fund. Akrobat, Value, and Europa are legally dependent on Axxion to act. As between themselves, Value and Europa are legally independent entities. The Akrobat Fund has no other funds under its umbrella besides Value and Europa.
- 5. Axxion has full and complete authority and discretion to purchase and sell securities for the Akrobat Fund (comprised of Value and Europa) and transacted in the GPC securities at issue in this litigation for the Akrobat Fund. Axxion has attorney-in-fact authority to institute legal action on behalf of the Akrobat Fund, Value, and Europa, for investment losses, including filing a motion for appointment as lead plaintiff in the present action.
- 6. I have attached as Exhibit A to this declaration a chart of Europa's transactions in GPC, as well as a loss analysis of those transactions.

I declare under penalty of perjury under the laws of the United States of America that the foregoing is true and correct.

Executed on October _____, 2007

Roman Mertes

Exhibit A Loss Analysis Axxion S.A. Luxemburg

Class Period: 12/5/05-7/24/07

Akrobat Fund - Europa

Transaction Type	Trade Date	No. of Shares	Price Per Share (EUR)	Cost/Proceeds (EUR)	Exch Rate**	Price Per Share (USD)	Cost/Proceeds (USD)
Purchase	05/24/06	200,000	€ 10.4500	-€ 2,093,185.00	1.2704	\$13.2757	-\$2,655,136.00
Purchase	05/26/06	100,000	€ 10.3000	-€ 1,031,595.00	1.2738	\$13.1201	-\$1,312,014.00
Purchase	07/03/06	25,000	€ 10.7700	-€ 269,703.88	1.2803	\$13.7888	-\$344,720.78
Purchase	07/17/06	22,000	€ 10.9000	-€ 240,209.70	1.2519	\$13.6457	-\$300,205.62
Purchase	07/18/06	103,000	€ 10.8500	-€ 1,119,276.33	1.2505	\$13.5679	-\$1,397,496.28
Purchase	08/23/06	100,000	€ 10.9960	-€ 1,101,299.40	1.2787	\$14.0606	-\$1,406,058.52
Purchase	08/25/06	100,000	€ 10.9810	-€ 1,099,797.15	1.2753	\$14.0041	-\$1,400,406.93
	Total purchases:	650,000		<i>-€ 6,955,066.46</i>			-\$8,816,038.12
Sale	11/27/06	-30,472	€ 15.8700	€ 482,815.25	1.3133	\$20.8421	\$635,099.59
Sale	12/04/06	-1,815	€ 15.8500	€ 28,674.60	1.3343	\$21.1487	\$38,384.81
Sale	12/06/06	-40,000	€ 16.1775	€ 646,079.35	1.3288	\$21.4967	\$859,866.48
Sale	12/06/06	-7,713	€ 15.8500	€ 122,017.67	1.3288	\$21.0615	\$162,447.20
	Total Sales:	-80,000		<i>€ 1,279,586.87</i>			\$1,695,798.07
	Retained Shares*	570,000	€ 9.1470	€ 5,213,790.00		<i>\$12.5518</i>	\$7,154,531.70

EURO Gain/Loss: -€ 461,689.59

USD Gain/Loss Based on daily conversion from Euros: \$34,291.65

USD Gain/Loss Based on conversion from Euros on 9/24/07: -\$650,335.96 1.4086 ***

^{*}Value of retained purchases is the mean trading price from 7/25/2007 to 9/24/2007.

^{**}The exchange rate is based upon the closing values of the Euro to USD as reported on Bloomberg.

^{***}The exchange rate is the closing value on 9/24/07, the date of lead plaintiff filings.